RxDoctor Payments Data

Elliott Bondi, MD

Pulmonary Disease · Brooklyn, NYNPI 1184667487

Payments from drug & device makers

$15,653in general payments, 2019–2025

Across 677 payments — averaging $23.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$2K
  • Boehringer Ingelheim$2K
  • Actelion Pharmaceuticals US, Inc.$2K
  • Insmed, Inc.$1K
  • AstraZeneca$784
  • Mallinckrodt Hospital Products Inc.$739
  • plus $7K from 41 others

What the payments were for

  • Food & beverage$15,39798%
  • Education$2562%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$15,653 in reported general payments places this provider in the 85th percentile of 1,115 pulmonary disease providers in New York.

See all pulmonary disease providers in New York

Medicare billing

Part B allowed, 2024
$109,440
Medicare patients
372
Services billed
1,558

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EsbrietPirfenidone25$260,797
Trelegy ElliptaFluticasone/Umeclidin/Vilanter268$199,616
Breo ElliptaFluticasone/Vilanterol131$57,855
FarxigaDapagliflozin Propanediol32$24,139
EliquisApixaban38$19,994
JanuviaSitagliptin Phosphate22$15,293
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr22$13,510
Spiriva RespimatTiotropium Bromide24$12,161
XareltoRivaroxaban20$11,269
Albuterol Sulfate HfaAlbuterol Sulfate318$10,155
EntrestoSacubitril/Valsartan17$9,118
SymbicortBudesonide/Formoterol Fumarate26$8,506
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$6,659
Incruse ElliptaUmeclidinium Bromide16$5,581
VascepaIcosapent Ethyl16$5,122

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta$2,291$276,562437 claims
Genentech USA, Inc.Esbriet$640$260,79725 claims
AstraZenecaFarxiga, Symbicort, Breztri Aerosphere$784$39,30369 claims
PfizerEliquis$187$19,99438 claims
MerckJanuvia$327$15,29322 claims
Boehringer IngelheimSpiriva Respimat$1,845$12,16124 claims
Johnson & JohnsonXarelto$134$11,26920 claims
NovartisEntresto$44$9,11817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,115 pulmonary disease providers in New York.

Other pulmonary disease in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →